| Affymax Shares Plunge On Hematide Study Data - Wall Street Journal |
|
|
Wall Street JournalBut shares plunged 65% to $8.07 in premarket action as the company said a subgroup of non-dialysis patients saw higher frequency of CSE events--which can ...Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for ... read more |